Trovo M, et al. - Researchers here performed a prospective phase II multicentric trial to assess if radical radiation therapy to all metastatic sites might improve the progression-free survival (PFS) in oligometastatic breast cancer patients. For this work, secondary endpoints were local control (LC), overall survival (OS) and toxicity. As per observations, patients with oligometastatic breast cancer treated with radical radiotherapy to all metastatic sites could achieve long-term progression-free survival, without significant treatment-related toxicity. While waiting for data from randomized trials, they suggested considering the use of radical radiation therapy to all metastatic sites in patients with oligometastatic breast cancer a valuable option and individualizing its recommendations.